modelJ01CE09
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | ProcaineBenzylpenicillin | |
| ATC code: | J01CE09 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 1200000 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 0.7 | L/h |
| other parameters in model implementation | ||
Procaine benzylpenicillin, also known as penicillin G procaine, is a combination of benzylpenicillin (penicillin G) and the local anesthetic procaine. It is an intramuscularly administered long-acting antibiotic used for various bacterial infections, such as syphilis, due to its prolonged release. Approved and widely used until recently in clinical settings, it is still used for select indications including syphilis and certain streptococcal infections.
Pharmacokinetics
Pharmacokinetic parameters estimated for healthy adult humans after intramuscular administration, as no recent primary articles with explicit compartment-model parameters were found.
References
Tshefu, A, et al., & Cousens, S (2015). Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet (London, England) 385(9979) 1758–1766. DOI:10.1016/S0140-6736(14)62285-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25842223
Baqui, AH, et al., & Black, RE (2015). Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. The Lancet. Global health 3(5) e279–e287. DOI:10.1016/S2214-109X(14)70347-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/25841891
Tshefu, A, et al., & Cousens, S (2015). Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet (London, England) 385(9979) 1767–1776. DOI:10.1016/S0140-6736(14)62284-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25842221
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)